The Jul.18 launch of GSK’s consumer healthcare spinoff Haleon on the London Stock Exchange – said to be the largest London listing in more than a decade – seems to have...
Sanofi and GSK are touting their latecomer protein-based Covid-19 vaccine as a potential game changer in the fight against the Omicron variant.
From its inception in 1881, SCI's principal objective has been to further the application of chemistry and related sciences into industry for the public benefit.
Both the Sanofi/GlaxoSmithKline partnership and US vaccine producer Moderna this week announced new advance purchase agreements with Canada for their Covid-19 vaccine...
Sanofi and GSK have agreed a deal with the EU to supply up to 300 million doses of their recombinant protein-based Covd-19 vaccine pending regulatory approval, which is...
Lagging behind other big names of late in announcing Covid-19 vaccine supply deals, French and British drugmakers Sanofi and GlaxoSmithkline together nailed down...
- GlaxoSmithKline (GSK) has agreed to make 1 billion doses of its AS03 adjuvant available to several developers of Covid-19 vaccines and plans to increase capacity to supply enough...
- GlaxoSmithKline has agreed an eight-year, $231 million, pact with South Korean CDMO Samsung Biologics to scale up manufacturing of biologics. The capacity Samsung provides will be...
Advertising Opportunities Print, Digital & Content Solutions
LinkedIn | Twitter